HOME > About Walvax > Product

Group A, C Meningococcal Polysaccharide Conjugate Vaccine, Freeze-dried

 Market Approval time
The product was on market officially in January 4, 2009
 Introduction
DESCRIPTION
Group A and C Meningococcal Polysaccharide Conjugate Vaccine is a product of group A and C meningococcal capsular polysaccharide antigens covalently bound to tetanus toxoid protein. It is presented as a white loose pellet, after reconstituted with accompanied diluent, the vaccine shall immediately turn into a clear, colorless solution.
One dose of 0.5ml contains:
Group A Meningococcal Polysaccharide………………………………………….10μg
Group C Meningococcal Polysaccharide…………………………………………10μg
Tetanus toxoid protein………………………………………………………….33~120μg
Lactose …………………………………………………………………………………….3~5mg
Sodium Chloride ……………………………………………………………..3.75~4.75mg
Diluent: Sterile water for injection

INDICATIONS
The vaccine is used to prevent diseases caused by the bacterium Neisseria Meningitidis group A orC in infants≦2 years of age, such as cerebrospinal meningitis and septicemia (generalized infection).
The vaccine does not prevent diseases caused by other serotypes of Meningococcal nor infection caused by pathogen causing meningitis or septicemia.

ADMINISTRATION AND DOSAGE
Reconstitute the vaccine with the accompanying diluents. Shake well and inject immediately. Each singe human dose is 0.5ml.
The vaccine should be administered intramuscularly in the deltoid region.
Infants 3 to 12 months of age shall be given three doses (0.5ml per dose) from age of 3 months, at intervals of one month.
Infants 13 to 24 months of age should follow recommended schedule of infants aged 3 to 12 months.
Children 2 to 5 years of age shall be given one dose (0.5ml).
Booster dose: The need for, or timing of a booster dose of the vaccine has not yet been determined.

PACKAGING
Vial. 1 dose. Each lyophilized vaccine is accompanied with 1 vial of 0.5ml diluent.

SHELF LIFE
24 months.